NovoPath is now recognised as the “Innovation Hub” for Precision Diagnostics within Diagnostics North East (DxNE), and now reports to the Research, Innovation and Enterprise strand of the Academic Health Science Centre (AHSC) – Newcastle Health Innovation Partners. It is seeking to facilitate a broad buy-in to Translational Bioimaging for which there appears to be significant interest. It will also act as a driver and facilitator for change in the relationships within the Integrated Laboratory Medicine (ILM) Directorate where there is now to be a phased integration of Cellular Pathology, Genetics and Haematological Oncology. The NovoPath Biobank (CePa) is now incorporated into NovoPath and we envisage that there will now be a stronger association with other Biobanks in Newcastle University to form a consortium, “Newcastle Biobanking”. The bringing together of these various strands to put Newcastle firmly on the map in Precision Diagnostics could be described as a virtual platform, which is being referred to as NovoPath.